PharmaResources (Shanghai) Co., Ltd Class A

PharmaResources (Shanghai) Co., Ltd Class A

SSZSE:301230
28.40
CNY
-1.48
(-4.95%)
0.16EPS
241.66P/E
6.98BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A carries a market capitalization of 6.98B, placing it among publicly traded companies globally. Its enterprise value stands at 6.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.98B
Enterprise Value6.86B

Important Dates

PharmaResources (Shanghai) Co., Ltd Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A has 181.46M shares outstanding.

Shares Outstanding181.46M

Valuation Ratios

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A trades at a trailing price-to-earnings ratio of 241.66. The price-to-sales ratio is 9.54, and the price-to-book ratio stands at 6.89.

PE Ratio241.66
PS Ratio9.54
PB Ratio6.89
P/TBV Ratio6.95

Enterprise Valuation

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A trades at an EV/EBITDA multiple of 258.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 258.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.86B versus a market cap of 6.98B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.46
EV / EBITDA258.51
EV / EBIT258.51

Financial Position

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A maintains a current ratio of 3.50, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.22, indicating elevated leverage, while an interest coverage ratio of 3.60 demonstrates adequate ability to service its debt obligations.

Current Ratio3.50
Quick Ratio1.74
Debt / Equity14.22
Debt / EBITDA5.44
Interest Coverage3.60

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 627,485.21 in revenue per employee across its workforce of 1,155.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee627,485.21
Employee Count1,155.00

Taxes

CNY

Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A recorded an income tax benefit of -3.58M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 25.02M, leaving 28.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-3.58M

Stock Price Statistics

CNY

As of the close on November 17, 2026, PharmaResources (Shanghai) Co., Ltd Class A's stock has gained approximately 16.39% over the past 52 weeks. The 50-day moving average sits at 32.75, while the 200-day moving average is 31.46.

52-Week Price Change16.39%
50-Day Moving Average32.75
200-Day Moving Average31.46

Income Statement

CNY

Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A generated 724.75M in revenue and converted that into 28.60M in net income, yielding earnings per share of 0.16. EBITDA reached 26.53M, while operating income came in at 43.18M.

Revenue724.75M
Gross Profit192.73M
Operating Income43.18M
Pretax Income25.02M
Net Income28.60M
EBITDA26.53M
EBIT26.53M
Earnings Per Share (EPS)0.16

Balance Sheet

CNY

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A holds 269.46M in cash and equivalents against 144.21M in total debt, resulting in a net debt position of -123.77M. Total book value stands at 1.01B, with working capital of 387.89M providing operational flexibility.

Cash & Cash Equivalents269.46M
Total Debt144.21M
Net Debt-123.77M
Equity (Book Value)1.01B
Book Value Per Share5.59
Working Capital387.89M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-79.01M

Margins

Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A posted a gross margin of 26.59, reflecting its pricing power and cost economics. The operating margin of 5.96 and net profit margin of 3.95 provide insight into operational efficiency.

Gross Margin26.59
Operating Margin5.96
Pretax Margin3.45
Profit Margin3.95
EBITDA Margin3.66

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A paid dividends of 0.28 per share. The dividend payout ratio of 178.96 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaResources (Shanghai) Co., Ltd Class A shareholders.

Dividend Per Share0.28
Payout Ratio178.96
Shareholder Yield1.22

Stock Splits

PharmaResources (Shanghai) Co., Ltd Class A's most recent stock split took place on July 16, 2026 with a 10:13 split ratio.

Last Split Date7/16/2026
Split Ratio10:13

Scores

As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A has an Altman Z-Score of 16.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.54